ARIKAYCE 590mg SPECIAL DRUG USE-RESULTS SURVEY

ARIKAYCE 590mg SPECIAL DRUG USE-RESULTS SURVEY - SPECIAL DRUG USE-RESULTS SURVEY of ARIKAYCE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046934

Enrollment

360

Registered

2022-02-25

Start date

2022-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-tuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with non-tuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC) who received Arikayce first time.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety - Incidence rate of the AEs / the ADRs, etc. Effectiveness - Proportion of patients who have achieved negative sputum culture, etc. - Annually confirming resistance of Mycobacterium avium complex (MAC) which is an indication of Arikayce.	—

Countries

Japan

Contacts

Public ContactMayumi Yamada

Insmed Godo Kaisya Drug Safety & Pharmacovigilance

Mayumi.Yamada@Insmed.com03-4212-8200

Outcome results